Revolution Medicines, Inc. — Director's Dealing 2021

Jun 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Revolution Medicines, Inc. (RVMD)
CIK: 0001628171
Period of Report: 2021-06-22

Reporting Person: Exter Neil (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-22	Common Stock	A	3617	—	Acquired	23615	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-22	Stock Option (Right to Buy)	$32.93	A	12659	Acquired	2031-06-21	Common Stock (12659)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	0	Indirect
Common Stock	19998	Indirect

Footnotes

F1: The Reporting Person is a partner of each of Third Rock Ventures GP II, L.P., Third Rock Ventures GP III, L.P. and Third Rock Ventures GP IV, L.P. which is the general partner of each of Third Rock Ventures II, L.P. ("TRV II), Third Rock Ventures III, L.P. ("TRV III") and Third Rock Ventures IV, L.P. ("TRV IV" and collectively with TRV II and TRV III, "the Funds"), respectively. The Reporting Person disclaims beneficial ownership over the shares held by the Funds, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

F2: TRV III directly holds 5,524,031 shares of Common Stock of the Issuer and TRV IV directly holds 1,419,900 shares of Common Stock of the Issuer.

F3: The shares are directly held in certain estate-planning trusts over which the Reporting Person may have voting and dispositive power. The Reporting Person disclaims beneficial ownership over the shares held by such trusts except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

F4: Includes 3,617 Restricted Stock Units.

F5: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 22, 2021 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.